Scanning patients on bisphosphonates within the first 3 years of therapy is just wasted effort, and may even be misleading clinically. That’s what researchers conclude after reanalysis of FIT trial data on some 6500 women taking either alendronate or placebo. Prof. Les Irwig of the University of Sydney talks about his team’s findings and what they mean for clinicians used to doing densitometric studies to reassure patients about the progress of their therapy.

This week’s news links:

This week’s Interview links: